Paige

Paige is an artificial intelligence company focused on transforming cancer diagnostics through advanced computational pathology. The company has developed AI-powered diagnostic applications that assist pathologists in detecting and classifying cancer across multiple tissue types, with specialized suites for prostate, breast, gastrointestinal, and pan-cancer analysis. Paige leverages a dataset of 25 million pathology slides from 800+ laboratory and medical institutions across 45+ countries.

The company's technology portfolio includes diagnostic and biomarker AI applications, foundation models (Virchow, Virchow2, Virchow2G, PRISM), and Paige Alba, a multi-modal AI co-pilot designed to integrate with pathology workflows through voice and text commands. Paige offers both direct diagnostic applications for pathology labs and licensing opportunities for third-party partners to build custom AI models. Their solutions analyze H&E-stained whole-slide images to support cancer detection, subtyping, and molecular biomarker identification directly from tissue samples.

Paige has secured backing from prominent investors including Goldman Sachs and KKR, and has been featured in major media outlets including Forbes, CNN, and Fox News. The company positions itself as a leader in applying foundation model technology to cancer care.

Paige is appropriate for organizations seeking specialized AI capabilities in cancer pathology backed by extensive training data. The company offers both ready-to-deploy diagnostic applications and foundation model technology for custom development, making it suitable for direct clinical implementation or research and development partnerships.

Healthcare organizations can expect AI assistance for pathologist workflows focused on cancer detection and classification, while pharmaceutical and biotech companies can license underlying technology to build proprietary applications. The multi-modal Alba co-pilot represents a distinctive approach to AI integration in pathology.

Paige operates exclusively in healthcare with specific focus on oncology and pathology. The company serves pathology laboratories, academic medical centers, pharmaceutical companies, and medical device manufacturers. Their applications address cancer detection across prostate, breast, gastrointestinal, and multiple other cancer types, with capabilities for molecular biomarker identification directly from H&E-stained tissue samples.

The company's dataset includes 350,000 patients and 200,000 cases with outcome and genomic data, supporting development of prognostic and predictive applications. Paige offers regulatory strategy services to help partners navigate healthcare-specific approval processes for AI-based diagnostic tools.

Large pathology laboratories and academic medical centers with high cancer case volumes requiring AI assistance for diagnostic workflows. Pharmaceutical companies, biotech firms, and medical device manufacturers developing computational pathology applications who need foundation models and regulatory expertise. Health systems implementing precision oncology programs that require molecular biomarker analysis from tissue samples.